openPR Logo
Press release

Future Outlook of US Cancer Biomarkers Market Poised to Achieve CAGR of 11.7% by 2023 – ABBOTT LABORATORIES, AFFYMETRIX (THERMO FISHER SCIENTIFIC), AGILENT TECHNOLOGIES, HOLOGIC, ROCHE HOLDING AG, 23ANDME, AMBRY GENETICS

09-27-2018 08:30 PM CET | Health & Medicine

Press release from: Market Prognosis

US Cancer Biomarkers Market Highlights
The US cancer biomarkers market is expected to register a CAGR 11.7%, during the forecast period, 2018 to 2023. Biomarkers are chemical, physical, or biological parameters, which can be used to indicate disease states. Oncology biomarkers offers high speed, non-invasive cancer diagnosis and believe to enhance cancer detection and screening. Major driving factors for the market are streamlined drug delivery process, noninvasive technology, and increased rates of survival.

Get your sample report now @ https://marketprognosis.com/sample-request/16897
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

Lung Cancer Lead the Cancer Biomarker Market in US
As per the American Cancer Society, lung cancer (both small cell and non-small cell) is the second most common cancer in both men and women (not counting skin cancer) and presence of numerous population with lung cancer in this country has made the lung cancer segment highest.

Key Developments in the Market:
• January 2018 u2013 Roche and GE has made a partnership to develop the integrated digital diagnostics platform to improve oncology and critical care treatment (This partnership will apply advanced analytics to in-vivo data from GE’s medical imaging and monitoring equipment with in-vitro data from Roche’s biomarker, tissue pathology, genomics and sequencing portfolio)
• January 2018 u2013 New biomarkers found for colorectal cancer (MYO5B)
• November 2017 u2013 Researchers found new biomarker for breast cancer (GIRK1)
• October 2017 u2013 ABBOTT has acquired ALERE

Major Players:
ABBOTT LABORATORIES, AFFYMETRIX INC. (THERMO FISHER SCIENTIFIC), AGILENT TECHNOLOGIES, HOLOGIC INC., ROCHE HOLDING AG, 23ANDME, AMBRY GENETICS, CELERA CORPORATION (QUEST DIAGNOSTICS) and ILLUMINA INC., among others.

Get Discount on this report @ https://marketprognosis.com/discount-request/16897
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

Increasing Usage in Drug Development
The application of biomarkers is not limited to medicine, but it also involves R&D. Drug development is a lengthy, costly, and cumbersome process. It can cost as high as a few USD billion, while the average time required could vary from 7 to 8 years to more than a decade, covering from preclinical to Phase IV (i.e. post marketing). Adding more complexity to it is the low success rate or approval from regulatory bodies. This leaves no option but to look for innovative methods, such as use of biomarker in drug development to decrease the overall period and cost.
The biomarker has the potential to meet the same goal by increasing efficiency of each phase, from preclinical to Phase IV. In preclinical study, the biomarker can be used identifying the drug components that are more likely to be tolerated in humans. In early clinical phase, the biomarker can be used to evaluate the drug-concentration response, and in later phases, stratification approaches (patient with and without biomarker) can be employed for looking at response in subgroups of patients. Predictive biomarkers have their usage in post marketing study too, as they can predict adverse events beforehand.
This ability of contributing to each phase has been successful in attracting the major pharma players to adopt the technology. Moreover, regulatory bodies have played a vital role in increasing the usage of biomarkers for R&D. In 2004, the U.S. Food and Drug Administration issued a white paper titled u2018Innovation or Stagnation, Challenge and Opportunity on the Critical Path to New Medical Products’. The document gives a detailed description of the reason for stagnation in drug development, and highlights the opportunities available. One of these opportunities is the use of biomarkers in drug development. This encouragement from regulatory bodies to use biomarkers has helped in market growth, and is expected to be the prime reason for growth in the future. The other factor, such as paradigm shift in healthcare from disease diagnosis to risk assessment or early diagnosis is driving the US cancer biomarker market.

High Cost of Diagnosis
According to a recent publication, approximately 13% of all deaths across the globe are caused due to cancer. It is estimated that the total cost of cancer in the United States was more than USD 263 billion in a single year. The usage of biomarker for screening, monitoring, diagnosing, and optimizing treatment has the potential to improve patient outcomes. On the contrary, the discovery of cancer biomarkers and the development and validation of assays are both complex and expensive. Because of the critical role that biomarkers play at all stages of disease, it is important that they undergo rigorous evaluation, including analytical validation, clinical validation, and assessment of clinical utility, prior to incorporation into routine clinical care. All these processes add up to the actual cost of cancer biomarkers and make them exorbitant and costly. Due to these reasons, biomarker development and validation costs are very much higher today. This particularly applies to the cancer field with the advent of novel cancer biomarkers. The costs of many of these new-generation technologies, like prognostic or predictive biomarkers, run into thousands of dollars per patient. So, this high cost of diagnosis is hindering the market growth. The other factor, such as reimbursement issues and need for immediate processing is also hindering the growth of the market.

For More Information, Please Visit @ https://marketprognosis.com/enquiry/16897
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

About Market Prognosis
We at Market Prognosis believe in giving a crystal clear view of market dynamics for achieving success in today’s complex and competitive marketplace through our quantitative & qualitative research methods.
We help our clients identify the best market insights and analysis required for their business thus enabling them to take strategic and intelligent decision.
We believe in delivering actionable insights for your business growth and success.

Contact us:
ProgMark Pvt Ltd,
Thane - 421501
India.
Contact No: +1 973 241 5193
Email: sales@marketprognosis.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Future Outlook of US Cancer Biomarkers Market Poised to Achieve CAGR of 11.7% by 2023 – ABBOTT LABORATORIES, AFFYMETRIX (THERMO FISHER SCIENTIFIC), AGILENT TECHNOLOGIES, HOLOGIC, ROCHE HOLDING AG, 23ANDME, AMBRY GENETICS here

News-ID: 1268232 • Views:

More Releases from Market Prognosis

Third-Party Logistics (3PL) Market Latest Study Focuses On Current, Future Innovations and Foreseen Till 2026 | FedEx, Exel Logistics, Menlo Worldwide Logistics, Ryder Logistics
Third-Party Logistics (3PL) Market Latest Study Focuses On Current, Future Innov …
The report covers a forecast and an analysis of the Third-Party Logistics (3PL) Market on a global and regional level. The study provides historical data for 2018, 2019, and 2020 along with a forecast from 2019 to 2026 based on revenue and volume. Overview of the Global Third-Party Logistics (3PL) Market: The report spread across 90 pages is an overview of the Global Third-Party Logistics (3PL) Market. These report study based on the Third-Party
Ride-Hailing Market: An Insight on the Important Factors and Trends Influencing by Top Key Players (Didi, Uber, Lyft, Gett, Hailo, Ola Cabs, Cabify, GoCatch) | Foreseen Till 2026
Ride-Hailing Market: An Insight on the Important Factors and Trends Influencing …
The report covers a forecast and an analysis of the Ride-Hailing Market on a global and regional level. The study provides historical data for 2018, 2019, and 2020 along with a forecast from 2019 to 2026 based on revenue and volume. Overview of the Global Ride-Hailing Market: The report spread across 90 pages is an overview of the Global Ride-Hailing Market. These report study based on the Ride-Hailing Market. It is a complete overview
COVID-19 Impact on Professional Indemnity Insurance Market 2021-2026: Industry Insight and Growth Strategy by Business Players - AIG, Chubb (ACE), Allianz, XL Group, AXA, Aviva
COVID-19 Impact on Professional Indemnity Insurance Market 2021-2026: Industry I …
The report covers a forecast and an analysis of the Professional Indemnity Insurance Market on a global and regional level. The study provides historical data for 2018, 2019, and 2020 along with a forecast from 2019 to 2026 based on revenue and volume. Overview of the Global Professional Indemnity Insurance Market: The report spread across 90 pages is an overview of the Global Professional Indemnity Insurance Market. These report study based on the Professional
Modular Construction Market Future Growth Explored in Latest Research Report by 2026 | Komatsu, Kiewit, Skanska, L&T, Taisei, ACS Group, Bouygues Construction
Modular Construction Market Future Growth Explored in Latest Research Report by …
The report covers a forecast and an analysis of the Modular Construction Market on a global and regional level. The study provides historical data for 2018, 2019, and 2020 along with a forecast from 2019 to 2026 based on revenue and volume. Overview of the Global Modular Construction Market: The report spread across 90 pages is an overview of the Global Modular Construction Market. These report study based on the Modular Construction Market. It

All 5 Releases


More Releases for Cancer

Cancer Therapeutics Market New Business Opportunities to Hit $180.19 billion by …
Surge in geriatric population and rise in the number of collaborations & partnerships to facilitate drug development are the key drivers of the global cancer therapeutics market. In addition, heavy inflow of investment in R&D activities has enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence boost the market. The high demand for personalized medicine along with high potential of emerging
Global Cancer Diagnostics Market Size, Trends & Growth Opportunity By Applicatio …
Cancer diagnostics is a process of detecting various proteins, biomarkers and certain symptoms that result in the detection of presence of cancerous tumour in patients. Detection of certain proteins and biomarkers which are prevalent in cancer disorder thereby results in diagnosis process. Cancer diagnostics includes usage of certain technology and devices for detection purpose. Increase in incidence of target diseases like cancer is key driving factor which is expected to boost
2019-2027 Oncology Nutrition Market is driven by Major Cancer Type - Head and Ne …
The "Global Oncology Nutrition Market Analysis to 2027" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of oncology nutrition market with detailed market segmentation by cancer type and geography. The global oncology nutrition market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the
Cancer Immunotherapy Market 2018 To 2025 - SWOT Analysis By Global Industry Reve …
The Cancer Immunotherapy Market research report provided by Crystal Market Research (CMR) is the most detailed study about Cancer Immunotherapy Market that is estimated to grow at a tremendous rate over the forecast period 2018-2025. This report contains precise and updated insights in respect with the leading market players and prevailing regions of the business. Cancer Immunotherapy Market By Product and Cancer Type - Global Industry Analysis And Forecast To 2025:
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance …
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine. These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch
Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung …
Researchmoz added Most up-to-date research on "Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung Cancer, Kidney Cancer, Bone Cancer, Breast Cancer, Prostate Cancer, And Others" to its huge collection of research reports. Tumor ablation is the removal of the tumor cells or tissue with minimally invasive procedure. Tumor ablation devices are consists of an applicator (catheter), which is introduced into the tumor under imaging guidance. For